胰岛素受体底物 1(insulin receptor substrate 1,IRS 1)表达与头颈部鳞状细胞癌预后的关系--系统综述和荟萃分析。

IF 2.5 3区 医学 Q3 ONCOLOGY Oncology Pub Date : 2024-08-26 DOI:10.1159/000541004
Deeksheetha Prabhuvenkatesh, Pratibha Ramani, Monal B Yuwanati, Gheena S
{"title":"胰岛素受体底物 1(insulin receptor substrate 1,IRS 1)表达与头颈部鳞状细胞癌预后的关系--系统综述和荟萃分析。","authors":"Deeksheetha Prabhuvenkatesh, Pratibha Ramani, Monal B Yuwanati, Gheena S","doi":"10.1159/000541004","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Head and neck squamous cell carcinoma (HNSCC) is the most common mucosal neoplasm that affects the head and neck region. It is the 6th most common cancer globally, most commonly seen in South Asian countries. Insulin receptor substrate 1 (IRS-1) like Insulin Receptor (IR) is an adaptor protein that integrates multiple transmembrane signals from growth factors and hormones, to regulate cell growth, survival, differentiation, and metabolism. Evidence suggests that IRS 1 plays a vital role in cancer progression and nodal metastasis. The aim is to assess the prognostic implications of the insulin receptor substrate 1 expression in head and neck squamous cell carcinoma from evidence-based results.</p><p><strong>Methods: </strong>A systematic literature search was done to identify articles describing Insulin receptor substrate 1 (IRS 1) and head and neck squamous cell carcinoma carried out for Pubmed, Cochrane, and Google Scholar, using MeSH terms.</p><p><strong>Results: </strong>A total of 486 cases of HNSCC were included in this systematic review. Out of 3 studies, increased/high expression of IRS 1 was 67%. 64% of the cases in Stage I and Stage II (TNM staging) showed higher expression of IRS 1, whereas 70% of the Stage III and Stage IV cases showed upregulation of IRS 1. IRS 1 was equally upregulated in cases with lymph node metastasis as well as in cases without any lymph node metastasis. 74% of the patients that showed high expression of IRS 1 showed high mortality during the follow-up period of 13 months.</p><p><strong>Conclusion: </strong>This review concluded that elevated levels of IRS 1 expression were associated with poor prognosis and increased lymph node metastasis.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ASSOCIATION OF INSULIN RECEPTOR SUBSTRATE 1 (IRS 1) EXPRESSION IN THE PROGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - A SYSTEMATIC REVIEW AND META ANALYSIS.\",\"authors\":\"Deeksheetha Prabhuvenkatesh, Pratibha Ramani, Monal B Yuwanati, Gheena S\",\"doi\":\"10.1159/000541004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Head and neck squamous cell carcinoma (HNSCC) is the most common mucosal neoplasm that affects the head and neck region. It is the 6th most common cancer globally, most commonly seen in South Asian countries. Insulin receptor substrate 1 (IRS-1) like Insulin Receptor (IR) is an adaptor protein that integrates multiple transmembrane signals from growth factors and hormones, to regulate cell growth, survival, differentiation, and metabolism. Evidence suggests that IRS 1 plays a vital role in cancer progression and nodal metastasis. The aim is to assess the prognostic implications of the insulin receptor substrate 1 expression in head and neck squamous cell carcinoma from evidence-based results.</p><p><strong>Methods: </strong>A systematic literature search was done to identify articles describing Insulin receptor substrate 1 (IRS 1) and head and neck squamous cell carcinoma carried out for Pubmed, Cochrane, and Google Scholar, using MeSH terms.</p><p><strong>Results: </strong>A total of 486 cases of HNSCC were included in this systematic review. Out of 3 studies, increased/high expression of IRS 1 was 67%. 64% of the cases in Stage I and Stage II (TNM staging) showed higher expression of IRS 1, whereas 70% of the Stage III and Stage IV cases showed upregulation of IRS 1. IRS 1 was equally upregulated in cases with lymph node metastasis as well as in cases without any lymph node metastasis. 74% of the patients that showed high expression of IRS 1 showed high mortality during the follow-up period of 13 months.</p><p><strong>Conclusion: </strong>This review concluded that elevated levels of IRS 1 expression were associated with poor prognosis and increased lymph node metastasis.</p>\",\"PeriodicalId\":19497,\"journal\":{\"name\":\"Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000541004\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:头颈部鳞状细胞癌(HNSCC头颈部鳞状细胞癌(HNSCC)是头颈部最常见的粘膜肿瘤。它是全球第六大常见癌症,最常见于南亚国家。胰岛素受体底物 1(IRS-1)与胰岛素受体(IR)一样是一种适配蛋白,可整合来自生长因子和激素的多种跨膜信号,从而调节细胞的生长、存活、分化和新陈代谢。有证据表明,IRS 1 在癌症进展和结节转移中起着至关重要的作用。本研究旨在从循证结果出发,评估头颈部鳞状细胞癌中胰岛素受体底物 1 表达对预后的影响:方法:在Pubmed、Cochrane和Google Scholar上使用MeSH术语进行系统文献检索,以确定描述胰岛素受体底物1(IRS 1)和头颈部鳞状细胞癌的文章:本系统综述共纳入了 486 例 HNSCC。在 3 项研究中,IRS 1 的增高/高表达率为 67%。64%的I期和II期(TNM分期)病例显示IRS 1表达较高,而70%的III期和IV期病例显示IRS 1上调。74% 的 IRS 1 高表达患者在 13 个月的随访期间死亡率较高:本综述认为,IRS 1表达水平升高与预后不良和淋巴结转移增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ASSOCIATION OF INSULIN RECEPTOR SUBSTRATE 1 (IRS 1) EXPRESSION IN THE PROGNOSIS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - A SYSTEMATIC REVIEW AND META ANALYSIS.

Introduction: Head and neck squamous cell carcinoma (HNSCC) is the most common mucosal neoplasm that affects the head and neck region. It is the 6th most common cancer globally, most commonly seen in South Asian countries. Insulin receptor substrate 1 (IRS-1) like Insulin Receptor (IR) is an adaptor protein that integrates multiple transmembrane signals from growth factors and hormones, to regulate cell growth, survival, differentiation, and metabolism. Evidence suggests that IRS 1 plays a vital role in cancer progression and nodal metastasis. The aim is to assess the prognostic implications of the insulin receptor substrate 1 expression in head and neck squamous cell carcinoma from evidence-based results.

Methods: A systematic literature search was done to identify articles describing Insulin receptor substrate 1 (IRS 1) and head and neck squamous cell carcinoma carried out for Pubmed, Cochrane, and Google Scholar, using MeSH terms.

Results: A total of 486 cases of HNSCC were included in this systematic review. Out of 3 studies, increased/high expression of IRS 1 was 67%. 64% of the cases in Stage I and Stage II (TNM staging) showed higher expression of IRS 1, whereas 70% of the Stage III and Stage IV cases showed upregulation of IRS 1. IRS 1 was equally upregulated in cases with lymph node metastasis as well as in cases without any lymph node metastasis. 74% of the patients that showed high expression of IRS 1 showed high mortality during the follow-up period of 13 months.

Conclusion: This review concluded that elevated levels of IRS 1 expression were associated with poor prognosis and increased lymph node metastasis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncology
Oncology 医学-肿瘤学
CiteScore
6.00
自引率
2.90%
发文量
76
审稿时长
6-12 weeks
期刊介绍: Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
期刊最新文献
The usefulness of serum interleukin-6 as a predictor of response to atezolizumab plus bevacizumab combination treatment in hepatocellular carcinoma. Identification of biomarkers for assessing treatment efficacy of chemotherapy plus nivolumab as the first line in patients with unresectable advanced or recurrent gastric cancer: a multicenter study. Dose-reduction of bevacizumab in atezolizumab plus bevacizumab therapy extends treatment duration with disease control in patients with hepatocellular carcinoma. Social characteristics of culturally and linguistically diverse cancer patients enrolled in early phase clinical trials in South-Western Sydney. Clinical impact of skeletal muscle mass and nutritional status in patients with recurrent or advanced gastric cancer treated with nivolumab.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1